CN106420785A - Medicine composition for treating community-acquired pneumonia - Google Patents

Medicine composition for treating community-acquired pneumonia Download PDF

Info

Publication number
CN106420785A
CN106420785A CN201611209345.3A CN201611209345A CN106420785A CN 106420785 A CN106420785 A CN 106420785A CN 201611209345 A CN201611209345 A CN 201611209345A CN 106420785 A CN106420785 A CN 106420785A
Authority
CN
China
Prior art keywords
parts
acquired pneumonia
pharmaceutical composition
treatment
community acquired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611209345.3A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Lidiya Medicine Technology Co Ltd
Original Assignee
Zhengzhou Lidiya Medicine Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Lidiya Medicine Technology Co Ltd filed Critical Zhengzhou Lidiya Medicine Technology Co Ltd
Priority to CN201611209345.3A priority Critical patent/CN106420785A/en
Publication of CN106420785A publication Critical patent/CN106420785A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Abstract

The invention discloses a medicine composition for treating community-acquired pneumonia, which is prepared from the main raw materials in parts by weight: 4 to 10 parts of ertapenem, 16 to 24 parts of allicin, 4 to 10 parts of amygdalin, 2 to 6 parts of cefixime, 1 to 3 parts of 3-n-butylphthalide, 0.8 to 1.4 parts of 3-n-butyl-4,5-dihydrophthalide, 1.5 to 1.9 parts of sulfoniazid, 1 to 3 parts of ampicillin, and 2 to 4 parts of swertiamarin. The medicine provided by the invention has the ability on treating community-acquired pneumonia, is strong in pertinence and scientific in compatibility so as to achieve the aim of comprehensive rehabilitation, treats both symptoms and root causes, and is short in treatment course, fast in effect, less in toxic and side effects, and low in cost.

Description

A kind of pharmaceutical composition treating community acquired pneumonia
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of pharmaceutical composition treating community acquired pneumonia.
Background technology
Community acquired pneumonia, refers to urge the infectious pulmonary parenchyma of trouble outside hospital (containing alveolar wall, that is, between sensu lato lung Matter) inflammation, the pneumonia fallen ill in incubation period after people institute including having clearly preclinical pathogenic infection.Community-acquired Pneumonia is to threaten one of Common infectious diseases of human health, its cause a disease former composition and resistant characterization in country variant, no There is notable difference between area, and As time goes on and constantly change.
Western medicine mainly adopts second and third generation cephalosporin, beta-lactam class at present, and fluoroquinolones is treated, though having certain Curative effect, but the transition with pathogenic microorganism, drug resistance phenomenon is on the rise, and side effect is larger, and some drugs are expensive, therefore Be difficult to popularity, and Chinese medicine then improve symptom and sign, Shorten the Treatment Process and improve overall treatment effect in terms of show huge Big advantage, but curative effect is slower, and long-term taking is big to Liver and kidney harm.
Therefore, it is badly in need of researching and developing a kind of suitable good effect, speed is fast, price is low, the Western medicine compound that has no toxic side effect.
Content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating community acquired pneumonia, to solve above-mentioned background The problem proposing in technology.
For achieving the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition treating community acquired pneumonia, the primary raw material according to weight portion is：Ertapenem 4- 10 parts, garlicin 16-24 part, amygdaloside 4-10 part, Cefixime 2-6 part, 3-n-butylphthalide 1-3 part, 3- normal-butyl -4, 5- dihydro Phthalide 0.8-1.4 part, sulfoniazid 1.5-1.9 part, ampicillin 1-3 part, swertiamarin 2-4 part.
As the further scheme of the present invention：The pharmaceutical composition of described treatment community acquired pneumonia, according to weight portion Primary raw material be：Ertapenem 6-7 part, garlicin 18-22 part, amygdaloside 5-7 part, Cefixime 3-5 part, 3- normal-butyl Phthalide 1-3 part, 3- normal-butyl -4,5- dihydro Phthalide 0.9-1.2 part, sulfoniazid 1.6-1.8 part, ampicillin 1-3 part, river deer tooth Dish hardship glycoside 2-4 part.
As the further scheme of the present invention：The pharmaceutical composition of described treatment community acquired pneumonia, according to weight portion Primary raw material be：7 parts of ertapenem, 20 parts of garlicin, 6 parts of amygdaloside, 4 parts of Cefixime, 2 parts of 3-n-butylphthalide, 1.0 parts of 3- normal-butyl -4,5- dihydro Phthalide, 1.7 parts of sulfoniazid, 2 parts of ampicillin, 3 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, garlicin, amygdaloside, cephalo gram are weighed by above-mentioned metering ratio Oxime, 3-n-butylphthalide, 3- Senkyunolide A, sulfoniazid, ampicillin, swertiamarin, sieve, machinery Add ultra-pure water after mixing, place in pharmacy mixer, mix 4-10min, control RSD≤5%, after mixing, tabletting low temperature are done Dry, at 4-10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
As the further scheme of the present invention：6min is mixed in concrete steps.
As the further scheme of the present invention：In concrete steps, temperature control is at 6 DEG C.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention has the ability for the treatment of community acquired pneumonia, with strong points, scientific compatibility, thus reaching comprehensively The purpose of rehabilitation, treating both the principal and secondary aspects of a disease, short treating period, instant effect, toxic and side effects are little, and cost is very cheap.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, Obviously, described embodiment is only a part of embodiment of the present invention, rather than whole embodiments.Based in the present invention Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of not making creative work, all Belong to the scope of protection of the invention.
Embodiment 1
A kind of pharmaceutical composition treating community acquired pneumonia, the primary raw material according to weight portion is：Ertapenem 4 Part, 15 parts of garlicin, 4 parts of amygdaloside, 2 parts of Cefixime, 1 part of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydro Phthalide 0.8 part, 1.5 parts of sulfoniazid, 1 part of ampicillin, 2 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, garlicin, amygdaloside, cephalo gram are weighed by above-mentioned metering ratio Oxime, 3-n-butylphthalide, 3- Senkyunolide A, sulfoniazid, ampicillin, swertiamarin, sieve, machinery Add ultra-pure water after mixing, place in pharmacy mixer, mixing 4min, control RSD≤5%, tabletting cold drying after mixing, At 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 2
A kind of pharmaceutical composition treating community acquired pneumonia, the primary raw material according to weight portion is：Ertapenem 6 Part, 18 parts of garlicin, 5 parts of amygdaloside, 3 parts of Cefixime, 1 part of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydro Phthalide 0.9 part, 1.6 parts of sulfoniazid, 1 part of ampicillin, 2 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, garlicin, amygdaloside, cephalo gram are weighed by above-mentioned metering ratio Oxime, 3-n-butylphthalide, 3- Senkyunolide A, sulfoniazid, ampicillin, swertiamarin, sieve, machinery Add ultra-pure water after mixing, place in pharmacy mixer, mixing 4min, control RSD≤5%, tabletting cold drying after mixing, At 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 3
A kind of pharmaceutical composition treating community acquired pneumonia, the primary raw material according to weight portion is：Ertapenem 7 Part, 20 parts of garlicin, 6 parts of amygdaloside, 4 parts of Cefixime, 2 parts of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydro Phthalide 1.0 parts, 1.7 parts of sulfoniazid, 2 parts of ampicillin, 3 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, garlicin, amygdaloside, cephalo gram are weighed by above-mentioned metering ratio Oxime, 3-n-butylphthalide, 3- Senkyunolide A, sulfoniazid, ampicillin, swertiamarin, sieve, machinery Add ultra-pure water after mixing, place in pharmacy mixer, mixing 6min, control RSD≤5%, tabletting cold drying after mixing, At 6 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 4
A kind of pharmaceutical composition treating community acquired pneumonia, the primary raw material according to weight portion is：Ertapenem 7 Part, 22 parts of garlicin, 7 parts of amygdaloside, 5 parts of Cefixime, 2 parts of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydro Phthalide 1.2 parts, 1.8 parts of sulfoniazid, 3 parts of ampicillin, 4 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, garlicin, amygdaloside, cephalo gram are weighed by above-mentioned metering ratio Oxime, 3-n-butylphthalide, 3- Senkyunolide A, sulfoniazid, ampicillin, swertiamarin, sieve, machinery Add ultra-pure water after mixing, place in pharmacy mixer, mixing 8min, control RSD≤5%, tabletting cold drying after mixing, At 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
Embodiment 5
A kind of pharmaceutical composition treating community acquired pneumonia, the primary raw material according to weight portion is：Ertapenem 8 Part, 25 parts of garlicin, 8 parts of amygdaloside, 6 parts of Cefixime, 2 parts of 3-n-butylphthalide, 3- normal-butyl -4,5- dihydro Phthalide 1.4 parts, 1.9 parts of sulfoniazid, 3 parts of ampicillin, 4 parts of swertiamarin.
A kind of preparation method of the pharmaceutical composition treating community acquired pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, ertapenem, garlicin, amygdaloside, cephalo gram are weighed by above-mentioned metering ratio Oxime, 3-n-butylphthalide, 3- Senkyunolide A, sulfoniazid, ampicillin, swertiamarin, sieve, machinery Add ultra-pure water after mixing, place in pharmacy mixer, mixing 8min, control RSD≤5%, tabletting cold drying after mixing, At 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie In the case of the spirit or essential attributes of the present invention, the present invention can be realized in other specific forms.Therefore, no matter From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power Profit requires rather than described above limits, it is intended that all in the implication and scope of the equivalency of claim by falling Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment only wraps Containing an independent technical scheme, only for clarity, those skilled in the art should for this narrating mode of description Using description as an entirety, the technical scheme in each embodiment can also form those skilled in the art through appropriately combined Understandable other embodiment.

Claims (6)

1. a kind of pharmaceutical composition treating community acquired pneumonia is it is characterised in that the primary raw material according to weight portion is：Strategic point Ta Peinan 4-10 part, garlicin 16-24 part, amygdaloside 4-10 part, Cefixime 2-6 part, 3-n-butylphthalide 1-3 part, 3- Normal-butyl -4,5- dihydro Phthalide 0.8-1.4 part, sulfoniazid 1.5-1.9 part, ampicillin 1-3 part, swertiamarin 2-4 part.
2. the pharmaceutical composition for the treatment of community acquired pneumonia according to claim 1 is it is characterised in that described treatment society The pharmaceutical composition of area's acquired pneumonia, the primary raw material according to weight portion is：Ertapenem 6-7 part, garlicin 18-22 part, Amygdaloside 5-7 part, Cefixime 3-5 part, 3-n-butylphthalide 1-3 part, 3- normal-butyl -4,5- dihydro Phthalide 0.9-1.2 part, Sulfoniazid 1.6-1.8 part, ampicillin 1-3 part, swertiamarin 2-4 part.
3. the pharmaceutical composition for the treatment of community acquired pneumonia according to claim 1 is it is characterised in that described treatment society The pharmaceutical composition of area's acquired pneumonia, the primary raw material according to weight portion is：7 parts of ertapenem, 20 parts of garlicin, Semen Armeniacae Amarum 6 parts of glycosides, 4 parts of Cefixime, 2 parts of 3-n-butylphthalide, 1.0 parts of 3- normal-butyl -4,5- dihydro Phthalide, 1.7 parts of sulfoniazid, ammonia 2 parts of benzyl XiLin, 3 parts of swertiamarin.
4. a kind of preparation method of the described pharmaceutical composition for the treatment of community acquired pneumonia as arbitrary in claim 1-3, its It is characterised by, concretely comprise the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh ertapenem, garlicin, amygdaloside, Cefixime, 3-n-butylphthalide, 3- Senkyunolide A, sulfoniazid, ampicillin, swertiamarin, sieve, and machinery mixes Add ultra-pure water afterwards, place in pharmacy mixer, mixing 4-10min, control RSD≤5%, tabletting cold drying after mixing, At 4-10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of community acquired pneumonia to temperature control.
5. according to claim 4 treatment community acquired pneumonia pharmaceutical composition preparation method it is characterised in that 6min is mixed in concrete steps.
6. according to claim 4 treatment community acquired pneumonia pharmaceutical composition preparation method it is characterised in that In concrete steps, temperature control is at 6 DEG C.
CN201611209345.3A 2016-12-23 2016-12-23 Medicine composition for treating community-acquired pneumonia Withdrawn CN106420785A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611209345.3A CN106420785A (en) 2016-12-23 2016-12-23 Medicine composition for treating community-acquired pneumonia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611209345.3A CN106420785A (en) 2016-12-23 2016-12-23 Medicine composition for treating community-acquired pneumonia

Publications (1)

Publication Number Publication Date
CN106420785A true CN106420785A (en) 2017-02-22

Family

ID=58215621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611209345.3A Withdrawn CN106420785A (en) 2016-12-23 2016-12-23 Medicine composition for treating community-acquired pneumonia

Country Status (1)

Country Link
CN (1) CN106420785A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270719A (en) * 2023-04-07 2023-06-23 广州宏康医药科技有限公司 Preparation method and preparation equipment of allicin composite preparation for treating pneumonia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101978980A (en) * 2010-11-04 2011-02-23 深圳市泰康制药有限公司 Szechuan lovage rhizome total phthalide extract
CN103783474A (en) * 2011-04-08 2014-05-14 彭书远 Allicin extraction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101978980A (en) * 2010-11-04 2011-02-23 深圳市泰康制药有限公司 Szechuan lovage rhizome total phthalide extract
CN103783474A (en) * 2011-04-08 2014-05-14 彭书远 Allicin extraction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
于志刚: "《内科常见疾病临床诊疗与思维 全科医师手册》", 31 July 2015, 杭州：浙江大学出版社 *
刘以敏: "《融合寒温 活用古方治儿疾 刘以敏学术思想与临床经验集》", 31 January 2015, 北京：中国中医药出版社 *
葛顺: "《抗感染药物临床实用手册》", 31 August 2012, 郑州：郑州大学出版社 *
邵素霞: "《帮您改善肺功能》", 30 September 2012, 石家庄：河北科学技术出版社 *
陈康等: ""獐芽菜苦苷的药理作用研究进展", 《现代药物与临床》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270719A (en) * 2023-04-07 2023-06-23 广州宏康医药科技有限公司 Preparation method and preparation equipment of allicin composite preparation for treating pneumonia

Similar Documents

Publication Publication Date Title
CN101444555B (en) Purely Chinese traditional medical film for curing oral ulcer and method for preparing same
CN106420785A (en) Medicine composition for treating community-acquired pneumonia
CN102370697A (en) Care cream for acute/chronic eczema and dermatitis
CN103386076B (en) A kind of mucomembranous nursing antibacterial gel composition and its application
CN102631407A (en) Antiphlogistic and analgesic mouth wash used for gingivitis
CN101040940A (en) Sanzi liquid for washing
CN106511452A (en) Drug composition for treating community-acquired pneumonia
CN103860474A (en) Doxycycline soluble powder production method
CN101991587A (en) Compound sulfadiazine injection and preparation method thereof
CN106511407A (en) Analgin with itching relieving effect and preparation method thereof
CN101530428A (en) Artificial bezoar and preparation method thereof
CN103622956B (en) Flucloxacillin sodium and amoxicillin sodium composition for injection
CN101259222B (en) Medicaments for treating bone fracture bone fracture disease
CN1372959A (en) Process for preparing patch 'Jingubitong'
CN106727591A (en) A kind of pharmaceutical composition for treating Streptococcus suis
CN101623297B (en) Medicine for treating beriberi
CN103330711B (en) Flucloxacillin sodium and amoxicillin sodium for injection
CN1061250C (en) Fast-acting antalgesic medical ointment series for external pain
CN1977860A (en) Sterized special agent for treating bromhidrosis
CN103417570A (en) Composition for treating bacterial diarrhea of pigs and preparation method thereof
CN106619666A (en) Pharmaceutical composition for treating swine dysentery
CN101461840A (en) External-use medicament for treating beriberi
CN105640958B (en) A kind of avocin and the pharmaceutical composition of sulbactam
CN104055771B (en) Flucloxacillin sodium and amoxicillin sodium powder ampoule agent for injection
CN103285034B (en) Medicine for treating chilblain and manufacturing method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170222

WW01 Invention patent application withdrawn after publication